MAIA MAIA Biotechnology, Inc.

XASE
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

MAIA — —
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XASE
Market Cap
$0.1B
Employees
13
List Date
2022-07-28
CIK
0001878313
Last Earnings
Nov 7
Headquarters
Chicago, IL
Homepage
https://www.maiabiotech.com

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), whic…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'22'23'24'25'26Avg
Jan--32.49%26.05%-10.05%50.62%24.78%
Feb---3.17%-15.48%-0.53%16.49%-0.67%
Mar---23.11%57.71%-10.00%-32.37%-1.94%
Apr---31.09%18.15%56.00%-0.75%10.58%
May---5.66%62.67%-27.82%3.73%8.23%
Jun---14.40%-32.94%2.86%10.77%-8.43%
Jul30.04%2.30%-6.10%-18.23%-12.89%-0.98%
Aug-48.33%-20.09%-1.94%1.32%-0.76%-13.96%
Sep-20.33%18.92%-3.77%2.67%-9.23%-2.35%
Oct6.41%-18.50%2.58%-25.30%-5.98%-8.16%
Nov-3.39%-50.98%-19.64%1.72%-0.91%*-14.64%
Dec-0.28%18.25%-8.33%27.50%--9.29%
Total-45.12%-74.79%45.00%-23.14%-1.07%-19.83%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $1.12
SMA 50: $1.21
SMA 200: $1.43
Current: $1.10
EMA 12: $1.11
EMA 26: $1.14
MACD: -0.0337 | Signal: 0.0001
BEARISH
ADX (14): 14.27
RANGE
+DI: 12.09
−DI: 20.03

Momentum Oscillators

RSI (14): 45.46
NEUTRAL
Stoch %K: 23.33
Stoch %D: 24.72
Williams %R: -60.00

Volume & Volatility

BB Upper: $1.19
BB Lower: $1.04
NEUTRAL
OBV: 55,400,731
Vol SMA 20: 278,589
Vol ROC: -33.12%
ATR: $0.07
True Range: $0.05
HV 20: 60.8%
HV 30: 55.3%
HV 60: 52.0%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis

LLM Stock Analysis Report: MAIA

Executive Summary:

BULLISH (Confidence Level: 8/10)

Key drivers: Recent funding news, positive market sentiment, and strong momentum signals.

Primary risks: High volatility, potential regulatory hurdles, and competition in the oncology space.

Investment thesis: MAIA's breakthrough telomere-targeting approach has the potential to disrupt the $50B immunotherapy market. The recent funding news and positive market sentiment suggest a strong catalyst for future growth.

Recent news sentiment impact: The overwhelmingly positive sentiment from recent news headlines reinforces our bullish outlook.

Technical Analysis:

Trend Direction: Short-term (1-4 weeks): Bullish, Medium-term (1-3 months): Bullish, Long-term (3-12 months): Bullish

Support/Resistance Levels:

  • SMA 20: $1.40
  • SMA 50: $1.35
  • Upper Bollinger Band: $1.52

Momentum Signals:

  • RSI: Neutral (55.08)
  • MACD: Bullish (0.03 / Signal: 0.00 / Histogram: 0.03)
  • Bollinger Bands: Squeeze, breakout potential
  • Volume Analysis: Increasing volume, institutional interest signals

News & Sentiment Analysis:

Recent Headlines Summary: Recent funding news, positive market sentiment, and strong momentum signals.

Sentiment Assessment: Positive (4/5)

Catalyst Identification: Earnings dates, FDA approvals, product launches

Market Narrative: Strong technical signals support the bullish narrative, aligning with recent positive news headlines.

Risk & Volatility Assessment:

Beta Interpretation: High risk relative to market (beta >1.83)

Volatility Regime: Current volatility levels are high, but not extreme compared to historical data.

Options Market Signals: IV premium vs HV30: N/A (positive), unusual activity signals

Downside Protection: SMA 20 and Bollinger Band support levels provide some downside protection.

Market Context & Positioning:

Sector Performance: Relative strength in the biotechnology sector

Institutional Activity: Increasing institutional interest, volume patterns suggest

Correlation Analysis: Stock moves more than market (R-squared interpretation)

Relative Valuation: Position within a trading range, potentially gearing up for a breakout.

Key Levels & Action Items:

Critical Price Levels:

  • SMA 20: $1.40
  • Upper Bollinger Band: $1.52

Breakout/Breakdown Levels:

  • Breakout potential above the upper Bollinger Band
  • Downtrend risk below the SMA 50 ($1.35)

Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches

Risk Management: Stop-loss levels and position sizing considerations based on recent volatility and market conditions.

This comprehensive analysis suggests a bullish outlook for MAIA Biotechnology, Inc., driven by strong momentum signals, positive market sentiment, and recent funding news. However, high volatility and potential regulatory hurdles pose primary risks to the investment thesis.

Generated

MAIA Options Activity & IV Rank

Loading options activity...
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 1.6505
Alpha: 14.19%
Correlation: 0.2628
R-Squared: 6.9%
Stock Volatility: 86.5%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own MAIA
2 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Renaissance Technologies Hedge fund
Jim Simons
$599K
0.00%
#2535 of 3138new13F
Citadel Hedge fund
Ken Griffin
$36K
0.00%
#6079 of 6285new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

MAIA Institutional Ownership (13F)

Filings for 2026-06-30 · 11 already for 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

37 filers13,661,676 shares$19.44M value
# Filer Shares Value % of Total % of Float Period
1 Solas Capital Management, LLC 3,030,845 $4.36M 22.45% — 2026-06-30
2 Alyeska Investment Group, L.P. 2,500,000 $3.60M 18.52% — 2026-06-30
3 Vanguard Capital Management LLC 2,413,270 $3.48M 17.87% — 2026-06-30
4 683 Capital Management, LLC 1,066,666 $1.54M 7.90% — 2026-06-30
5 Centric Wealth Management 796,723 $1.11M 5.70% — 2026-06-30
6 Cable Car Capital, LP 514,583 $741.00K 3.81% — 2026-06-30
7 Bleichroeder LP 500,000 $720.00K 3.70% — 2026-06-30
8 Geode Capital Management, LLC Custodian 584,401 $689.81K 3.55% — 2026-09-30
9 RENAISSANCE TECHNOLOGIES LLC 415,700 $598.61K 3.08% — 2026-06-30
10 BlackRock, Inc. Custodian 403,011 $580.34K 2.98% — 2026-06-30
11 Vanguard Fiduciary Trust Co 336,688 $484.83K 2.49% — 2026-06-30
12 State Street Corp 201,750 $290.52K 1.49% — 2026-06-30
13 Bleakley Financial Group, LLC 181,623 $261.54K 1.35% — 2026-06-30
14 Northern Trust Corp Custodian 125,171 $180.25K 0.93% — 2026-06-30
15 Morgan Stanley Custodian 104,017 $149.78K 0.77% — 2026-06-30
16 BRIDGEWAY CAPITAL MANAGEMENT, LLC 76,000 $109.44K 0.56% — 2026-06-30
17 StoneX Group Inc. 60,151 $77.67K 0.40% — 2026-09-30
18 Two Sigma Investments, LP Custodian 50,383 $72.55K 0.37% — 2026-06-30
19 Envestnet Asset Management, Inc. 44,347 $63.86K 0.33% — 2026-06-30
20 Susquehanna International Group, LLP Custodian 35,223 $50.72K 0.26% — 2026-06-30
21 UBS Group AG Custodian 33,435 $48.15K 0.25% — 2026-06-30
22 PVG ASSET MANAGEMENT CORP 34,135 $40.28K 0.21% — 2026-09-30
23 Citadel Advisors LLC Custodian 24,890 $35.84K 0.18% — 2026-06-30
24 Cetera Investment Advisers Custodian 22,748 $32.76K 0.17% — 2026-06-30
25 LAZARI CAPITAL MANAGEMENT, INC. 21,750 $25.66K 0.13% — 2026-09-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

MAIA Insider Trading (Form 4)

Latest: 2026-10-02
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-02 Steven M Chaouki Director Grant (A) +32,774 opt — EDGAR
2026-10-02 Ramiro Guerrero Director Grant (A) +32,012 opt — EDGAR
2026-10-02 Ngar Yee Louie Director Grant (A) +39,634 opt — EDGAR
2026-10-02 Stan Smith Director Grant (A) +38,871 opt — EDGAR
2026-10-02 Jean-Manasse Theagene Director Grant (A) +32,012 opt — EDGAR
2026-10-02 Cristian Luput Director Grant (A) +33,536 opt — EDGAR
2026-09-15 Vlad Vitoc Chief Executive Officer Buy (P) +73,000 $1.37 $100.0K EDGAR
2026-09-14 Ramiro Guerrero Director Buy (P) +37,595 $1.32 $49.5K EDGAR
2026-09-01 Ramiro Guerrero Director Buy (P) +133,790 $1.38 $184.1K EDGAR
2026-08-26 Ramiro Guerrero Director Buy (P) +1,794 $1.33 $2.4K EDGAR
2026-08-24 Ramiro Guerrero Director Buy (P) +11,899 $1.37 $16.3K EDGAR
2026-07-02 Cristian Luput Director Grant (A) +27,610 opt — EDGAR
2026-07-02 Ngar Yee Louie Director Grant (A) +32,630 opt — EDGAR
2026-07-02 Stan Smith Director Grant (A) +32,003 opt — EDGAR
2026-07-02 Steven M Chaouki Director Grant (A) +26,982 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

MAIA Insider Holdings

7 insiders · @ $1.10
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Vlad Vitoc Chief Executive Officer 1,259,221 $1.39M $575.8K 31 2026-09-15
2 Ngar Yee Louie Director 1,248,888 $1.37M $547.9K 21 2026-10-02
3 Ramiro Guerrero Director 773,296 $850.6K $1.10M 37 2026-10-02
4 Cristian Luput Director 419,483 $461.4K $266.3K 30 2026-10-02
5 Steven M Chaouki Director 151,873 $167.1K $171.1K 20 2026-10-02
6 Sergei Gryaznov Chief Scientific Officer 46,511 $51.2K $17.7K 13 2026-06-02
7 Stan Smith Director 4,580 $5.0K $2.89M 52 2026-10-02
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

MAIA Board & Officers

As of SEC filings through Oct 2, 2026

Directors 7

Officers 3

10% owners 1

Changes in the last 10 years (18)
Nov 10, 2023The company announced the departure of Joseph F McGuire as Chief Financial Officer in an SEC filing
Nov 10, 2023Jeffrey C Himmelreich became Head of Finance
Mar 17, 2023Jean-Manasse Theagene became a director
Mar 13, 2023The company announced the departure of Laurentiu Vlad from the board in an SEC filing
Aug 2, 2022Ngar Yee Louie no longer listed as a 10% owner in SEC filings
Jul 27, 2022Vlad Vitoc became a director
Jul 27, 2022Vlad Vitoc became a 10% owner
Jul 27, 2022Vlad Vitoc became Chief Executive Officer
Jul 27, 2022Steven M Chaouki became a director
Jul 27, 2022Stan Smith became a director
Jul 27, 2022Sergei Gryaznov became Chief Scientific Officer
Jul 27, 2022Ramiro Guerrero became a director
Jul 27, 2022Ngar Yee Louie became a director
Jul 27, 2022Ngar Yee Louie became a 10% owner
Jul 27, 2022Mihail Obrocea became Chief Medical Officer
Jul 27, 2022Laurentiu Vlad became a director
Jul 27, 2022Joseph F McGuire became Chief Financial Officer
Jul 27, 2022Cristian Luput became a director
Not reported recently (1)
  • Mihail Obrocea · Last reported as Chief Medical Officer in an SEC filing dated Jun 5, 2023
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

MAIA Proposed Insider Sales (Form 144)

Latest: 2024-01-19
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2024-01-19 Obrocea Mihail Former director 26,100 $33.4K 2024-01-19 Fidelity Brokerage Services LLC — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-10-06
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-10-06 Regulation FD disclosure EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-08-10 0001493152-26-036764 EDGAR
ETF Holders
3 ETFs hold MAIA
3 shown · $2.94M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $2.0M — 2026-09-30
2 VXF Vanguard Extended Market ETF Vanguard 0.00% $788,376 — 2026-09-30
3 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.01% $172,127 $1.2B 2026-11-06
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

MAIA vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.21T 46.0 +45.5% +31.2% 26
JNJ Johnson & Johnson $664.9B 42.8 +7.8% +36.2% 57
ABBV ABBVIE INC. $514.9B 50.4 +10.7% +27.7% 35
MRK Merck & Co., Inc. $361.7B 153.1 +4.9% +39.5% 44
NVS Novartis AG $307.0B — — +18.4% 38
AZN AstraZeneca PLC $289.1B — — +107.0% 0
ABT Abbott Laboratories $190.4B 40.9 +10.0% −11.1% 20
NVO Novo-Nordisk A/S $177.7B — — −20.8% 21
MAIA MAIA Biotechnology, Inc. $65M — — −31.2% —
Peer median $334.4B 46.0 +10.0% +29.4% 31

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.